Agrylin anagrelide

Drug Class

Phosphodiesterase 3 inhibitor

Mechanism

Inhibits megakaryocyte maturation and hypermaturation, reducing platelet production.

Approved Indication

Treatment of patients with thrombocythemia secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis.

What This Means For Patients

Agrylin is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (1997) — Sources
• EMA — Approved (2004) — Sources

Pivotal Clinical Evidence

• PT-1 — Harrison et al., N Engl J Med 2005 (NCT00168480) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020333s035lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/xagrid